Phenotypic differences and treatment persistence in a large multicentre cohort of axial psoriatic arthritis.

OBJECTIVE

To compare clinical features across three axial psoriatic arthritis (PsA) phenotypes: (i) isolated axial PsA, (ii) axial PsA with oligoarticular involvement (axial PsA+oligo), and (iii) axial PsA with polyarticular disease (axial PsA+poly), and assess persistence of first-line biologic and targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs).

METHODS

Baseline demographic, clinical, therapeutic, laboratory, and imaging data were retrospectively collected. Kaplan-Meier analysis evaluated treatment persistence, and LASSO Cox regression identified baseline factors associated with discontinuation.

RESULTS

Among 621 patients, 175 (28.2%) had isolated axial PsA, 252 (40.6%) axial PsA+oligo, and 194 (31.2%) axial PsA+poly. Psoriasis was more frequent in isolated axial PsA and axial PsA+oligo than in axial PsA+poly (82.3% and 82.1% vs 66.1%; P < 0.001), with lower Human Leukocyte Antigens (HLA)-B27 positivity in axial PsA+poly (10.9% vs 18.9% in isolated axial PsA and 21.6% in axial PsA+oligo; P = 0.02). Sacroiliitis was more frequent in isolated axial PsA (70.3%) and axial PsA+oligo (65.7%) than in axial PsA+poly (53.6%, P < 0.001), whereas spondylitis was more frequent in axial PsA+poly (15.0% vs 8.3% in axial PsA+oligo and 6.3% in isolated axial PsA; P < 0.001). Treatment persistence was longest in axial PsA+oligo (62 months, 95% CI 43-67) and shortest in axial PsA+poly (38 months, 95% CI 24-49) (P = 0.006). Higher VAS global pain was associated with shorter persistence (aHR 1.010, 95% CI 1.003-1.018, P = 0.009), whereas HLA-B27 positivity (aHR 0.56, 95% CI 0.32-0.99, P = 0.045) with longer persistence.

CONCLUSION

Treatment persistence in axial PsA varies according to clinical phenotypes, HLA-B27 status and pain, supporting the relevance of phenotypic stratification in clinical practice.